On October 7, HBM HOLDINGS-B fell 6.74% in regular trading, with the stock price dropping to 12.77 and turnover reaching 834.16 million Hong Kong dollars. The decline occurred amid a broader pullback in the biotechnology sector, where the overall sentiment turned cautious.

Within the biotechnology sector, other major names also faced selling pressure, including AKESO down 1.99%, INNOVENT BIO down 2.11%, CANSINOBIO down 6.31%, BEONE MEDICINES down 1.72%, and 3SBIO down 2.62%. The sector-wide weakness likely contributed to the negative performance of HBM HOLDINGS-B.

HBM HOLDINGS-B is a clinical-stage biopharmaceutical company focused on developing innovative therapies in immuno-oncology and immunologic diseases. Its proprietary antibody platforms include Harbour Mice, HBICE, HBICA, and a monoclonal B cell screening platform. Key product candidates include batoclimab, HBM9378, HBM7020, TCE programs, and prusubicin, targeting indications such as myasthenia gravis, COPD, asthma, autoimmune diseases, melanoma, colorectal cancer, and solid tumors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)